Thu.Apr 25, 2024

article thumbnail

Merck CEO Davis dubs Keytruda market exclusivity loss as 'more of a hill than a cliff'

Fierce Pharma

Merck touted newly approved Winrevair and what the emergence of the potential blockbuster means for the company as it faces the LOE of Keytruda.

Marketing 306
article thumbnail

Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines

MedCity News

Regeneron Pharmaceuticals is collaborating with CRISPR technologies startup Mammoth Biosciences to develop in vivo gene-editing therapies. The deal marks the third pharmaceutical industry partnership for Mammoth, which initially focused on developing CRISPR-based diagnostics. The post Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines appeared first on MedCity News.

Medicine 134
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novo Nordisk lands back in Sanders' crosshairs, this time over steep costs of Ozempic and Wegovy

Fierce Pharma

Just a few months after laying into CEOs from Bristol Myers Squibb, Merck & Co., and Johnson & Johnson about the high costs of their drugs, Sen. | Just a few months after laying into CEOs from Bristol Myers Squibb, Merck & Co. and Johnson & Johnson about the high costs of their drugs, Sen. Bernie Sanders, I-Vermont, is taking Novo Nordisk to task for allegedly turning its blockbuster GLP-1s Ozempic and Wegovy into “luxury goods.

298
298
article thumbnail

How Will Walgreens’ Expansion into Specialty Pharmacy Affect the Industry?

MedCity News

Walgreens announced that it is expanding its specialty pharmacy offerings. Experts think that this move could yield several strategic benefits, given the higher profit margins associated with specialty medications compared to traditional drugs. They also think Walgreens’ move could lead to greater competition, consolidation and innovation within the broader pharmacy industry.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

AstraZeneca CEO says platform deals largely done after M&As in vaccines, radioligand, cell therapy

Fierce Pharma

After AstraZeneca’s recent acquisitions of various technologies across different therapeutic areas, some investors started to wonder if the British pharma is stretching too thin. | After AstraZeneca’s recent acquisitions of various technologies across different therapeutic areas, some investors started to wonder if the British pharma is stretching too thin.

Pharma 290
article thumbnail

Examining the Usefulness of the Lean Startup Method in Building Health Tech Products

MedCity News

How health tech startups can successfully adapt the principles to their business ideas The post Examining the Usefulness of the Lean Startup Method in Building Health Tech Products appeared first on MedCity News.

117
117

More Trending

article thumbnail

With All the Organ Donation Scrutiny, Ask: What Can We Do to Reduce the Need? 

MedCity News

People do not have to die waiting for a kidney. A VBC approach can lead to earlier identification of kidney disease and better management in its earlier stages. The post With All the Organ Donation Scrutiny, Ask: What Can We Do to Reduce the Need? appeared first on MedCity News.

article thumbnail

Utility Therapeutics wins FDA nod for UTI antibiotic that has been on the market in Europe for 40-plus years

Fierce Pharma

For the first time in more than 20 years, the FDA has approved a | For the first time in more than 20 years, the FDA has approved a treatment for uncomplicated urinary tract infections. And the endorsement has come for an oral antibiotic that has been available in Europe for more than 40 years. It’s an odd set of circumstances and a dose of foresight by Utility Therapeutics that bring Pivya (pivmecillinam) to the market in the United States in the therapy’s golden years.

FDA 246
article thumbnail

MPE launches English Myeloma and AL Amyloidosis European Clinical Trial Navigator

PharmaTimes

The tool will help people find out about clinical trials for myeloma, MGUS, SMM and AL amyloidosis

Patients 109
article thumbnail

Collaborative partnerships key to clearing the path for new biopharma products

Fierce Pharma

Where innovation meets obstacles and the cost of drug development skyrockets, the key to unlocking success of groundbreaking products in the biopharma industry will rely heavily on strategic | Collaborative partnerships key to clearing the path for new biopharma products

Biopharma 246
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Eli Lilly Purchases Nexus Pharmaceutical Injectables Manufacturing Plant

Pharmaceutical Commerce

The deal further grows the Big Pharma company’s US production capabilities, especially when it comes to global parenteral products.

article thumbnail

Fierce Pharma Asia—Novartis reworks China ties; Neurocrine-Takeda med passes depression test; Enhertu nears key readout

Fierce Pharma

Novartis has started cutting ties with Chinese contractors amid a potential threat from the BIOSECURE Act. | Novartis has started cutting ties with Chinese contractors amid a potential threat from the BIOSECURE Act. A depression drug candidate that Neurocrine licensed from Takeda succeeded in a phase 2 trial. AstraZeneca and Daiichi Sankyo's Enhertu is on the cusp of a key readout in HER2-low breast cancer.

Pharma 246
article thumbnail

Supporting female leaders to advance cell and gene therapies

European Pharmaceutical Review

Four key barriers to female career progression were explored during a panel at the UK 2024 Advanced Therapies conference in March. Hosted by members of the professional women’s networking group CGT Circle, the session explored factors that could be contributing to the current imbalance for women in leadership positions within the cell and gene therapy (CGT) sector.

article thumbnail

Takeda ditches industry trade group BIO following exits by WuXi AppTec, Pfizer and UCB

Fierce Pharma

Joining a list that recently includes Pfizer, UCB and WuXi AppTec, Takeda Pharmaceuticals is the latest drugmaker to pull out of prominent industry lobbying group the Biotechnology Innovation Organ | The company opted not to renew its Biotechnology Innovation Organization (BIO) membership for its next fiscal year.

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Pharma Pulse 4/25/24: Advocate for Greater Pharmacy Technician Roles, Global COVID-19 Vaccines Strategic Research Report 2024 & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 103
article thumbnail

Sanofi leans on COPD as 'next major growth pillar' for its immunology star Dupixent: CEO

Fierce Pharma

Even as new Sanofi drugs like Beyfortus and Altuviiio come into their own, the French pharma’s immunology powerhouse Dupixent shows no signs of slowing down. | Even as new Sanofi drugs like Beyfortus and Altuviiio come into their own, the French pharma’s immunology powerhouse Dupixent shows no signs of slowing down. In fact, Sanofi is already gearing up for the antibody’s potential debut in what CEO Paul Hudson dubbed the drug’s “next major growth pillar.

242
242
article thumbnail

Cidara buys back rights to flu therapy from J&J for $85m

Pharmaceutical Technology

Marking another chapter in the long-running saga, J&J has deprioritised the CD388 influenza programme allowing Cidara to buy it back.

98
article thumbnail

Navigating the Impact of the Inflation Reduction Act: Assessing Current Realities and Future Trajectory

Fierce Pharma

Navigating the Impact of the Inflation Reduction Act: Assessing Current Realities and Future Trajectory jpiatt Thu, 04/25/2024 - 14:30

130
130
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

CMT Research Foundation funds study investigating treatment for CMT1X disease

PharmaTimes

X-linked Charcot-Marie-Tooth is the second most common form of the rare peripheral neuropathy disease

98
article thumbnail

'The Top Line': A look at pharma revenue rankings

Fierce Pharma

Fierce Pharma publishes a yearly special report highlighting the top 20 pharmas based on their revenue. | This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Staff Writer Kevin Dunleavy are diving into our annual top pharma companies by revenue special report.

Pharma 130
article thumbnail

Generics propelling pharmaceutical parenteral packaging market

European Pharmaceutical Review

Research on the global pharmaceutical parenteral packaging market by InsightAce Analytic Pvt. Ltd. has predicted that the sector will value $18.85 billion by 2031. This is aligned with a CAGR of 4.47 percent between 2024 and 2031. Main drivers for the market were reported to be rising popularity of generics together with blockbuster and other small-molecule drugs going off-patent globally.

article thumbnail

Which AI Applications Interest Your Employer Clients the Most? Where Will They Have the Greatest Impact?

MedCity News

If you advise self-insured employers on healthcare benefits, your expert insights will help provide a comprehensive perspective of the state of healthcare benefits for employers in our second annual survey, the 2024 Benefit Consultant Sentiment THE INDEX. The post Which AI Applications Interest Your Employer Clients the Most? Where Will They Have the Greatest Impact?

article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Stress impact on protein particle formation for monoclonal antibody formulation

European Pharmaceutical Review

A study has determined that for biologics subject to multiple stresses during bioprocessing and manufacturing , “exposure to air-liquid interfacial dilatational stress is the predominant mechanism impacting protein particle formation, [both] at the interface and in the bulk solution” Researchers established a “unique” set-up using a peristaltic pump and a Langmuir-Pockels trough to study the impact of hydrodynamic shear stress due to pumping and interfacial dilatational stress, on the form

article thumbnail

Debunking the Myths Around Patient Financing

MedCity News

Embedding patient financing options into the billing process presents a very clear solution for providers and patients to balance affordability and increase collectability. The post Debunking the Myths Around Patient Financing appeared first on MedCity News.

article thumbnail

FDA Reports on Status of Postmarketing Requirements and Postmarketing Commitments

PharmaTech

The majority of PMCs/PMRs are proceeding according to schedule.

FDA 64
article thumbnail

Mapping the Global Sustainable Innovation Landscape

Clarivate

Sustainability has become increasingly critical for organizations to demonstrate their missions and address some of the world’s most pressing challenges. Much like digital transformation, driving sustainability requires organizations to transform every division of their business and integrate in the corporate strategy. As part of the 2030 Agenda for Sustainable Development, the United Nation (UN) has outlined seventeen Sustainable Development Goals (SDGs) as a blueprint for peace and prosperity

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Merck plans €300m investment at new German research centre

Pharmaceutical Technology

Merck has announced an investment of more than €300m ($320.8m) in a new Life Science Research Center at its global headquarters in Darmstadt, Germany.

59
article thumbnail

Study Finds Relationship Between Uncontrolled Severe Asthma, Exacerbations and Health Care Resource Use

Pharmacy Times

The findings emphasize a need for guideline-based care delivery for patients with severe asthma, particularly for patients who are facing social disparities within health care.

article thumbnail

Pharmatech Insights – Innovations in Cell & Gene Therapy

PharmaTech

What innovations can help drug manufacturers and developers mitigate risks, reduce turnaround time, and increase success in early phase Cell & Gene therapy development?

article thumbnail

Advancement in Stem Cell Transplantation: Improving Outcomes for Patients With Blood Cancer

Pharmacy Times

Advances, challenges, and promising innovations emerge.

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A